Earnings season brings information ranging from news tidbits, like a new brand name for BioMarin Pharmaceutical Inc.’s hemophilia gene therapy, to submissions including Sanofi’s novel biologic sutimlimab and new indications for Merck & Co. Inc.’s Keytruda and Novartis AG’s Entresto.
The ranks of breakthrough therapy designations rose by two, with BTDs announced by GlaxoSmithKline PLC (Benlysta for lupus nephritis)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?